Accordingly, animal models used to study the onset of, but also progression of NAFLD to later stages of the disease like NASH or even fibrosis and cirrhosis, should incorporate the following criteria: (i) the pathological patterns and histological alterations found in the different stages of the disease in humans and (ii) the general physiological alterations associated with the disease development in humans (e.g., weight gain, insulin resistance but also impaired intestinal barrier function and adipocytokine release from adipose tissue). Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.